Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6592451 | 0.84 | KMT2A (0.47) | ALDH1A1KMT2APOLBTSHRRECQL | |
| SCHEMBL5508290 | 0.77 | LMNA (0.43) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL5508296 | 0.77 | LMNA (0.43) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL6590244 | 0.73 | MAPT (0.54) | ALDH1A1MAPTLMNAKMT2APOLB | |
| SCHEMBL6595196 | 0.72 | CNR2 (0.42) | MAPTKMT2ATSHRRECQLSMN1; SMN2 | |
| SCHEMBL15962162 | 0.72 | MAPT (0.52) | ALDH1A1MAPTKMT2APOLBHTT | |
| SCHEMBL6173457 | 0.72 | MAPT (0.52) | ALDH1A1MAPTKMT2APOLBHTT | |
| SCHEMBL28408689 | 0.72 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNAMAPK1NPSR1 | |
| SCHEMBL2993869 | 0.71 | NR3C2 (0.48) | ALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL2993871 | 0.71 | NR3C2 (0.48) | ALDH1A1MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189883-B1 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6548533-B2 | Pyrrolidine carboxylic Acid or ester derivatives are useful for treating alpha 4 beta 1 mediated cell adhesion | AVENTIS PHARMA LIMITED (GB) | 2003-04-15 | — | — | US | disclosed |
| US-20020094994-A1 | Substituted pyrrolidines | AVENTIS PHARMA LIMITED (GB) | 2002-07-18 | — | — | US | disclosed |
| EP-1189883-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | Aventis Pharma Limited (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000068195-A2 | SUBSTITUTED PYRROLIDINES AS CELL ADHESION INHIBITORS | AVENTIS PHARMA LIMITED (GB) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094994-A1 | Substituted pyrrolidines | VCAM1, ITGB1, ITGA1 | ALDH1A1 438/4885MAPT 4820/4885LMNA 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.